ImmunoScape Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • Angel

  • Investors
  • 9

ImmunoScape General Information

Description

Developer of an immune profiling system and analytical tools designed to support immunotherapy clinical development. The company's tools offer immune cell profiling technologies, antigen-specific T-cell identification, and an online analytical pipeline, enabling companies to gain valuable information on the efficacy and safety of immunotherapies across the research, development, and clinical phases.

Contact Information

Website
www.immunoscape.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Scotts Road
  • Number 24-10
  • Singapore, 228208
  • Singapore
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 1 Scotts Road
  • Number 24-10
  • Singapore, 228208
  • Singapore

ImmunoScape Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunoScape Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Angel (individual) 04-Mar-2026 Completed Startup
6. Later Stage VC (Series B2) 13-Jun-2025 Completed Pre-Clinical Trials
5. Grant 18-Sep-2024 Completed Pre-Clinical Trials
4. Later Stage VC (Series B) 14-Apr-2021 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 11-Aug-2020 Completed Pre-Clinical Trials
2. Accelerator/Incubator 16-May-2019 $2.37M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 26-Oct-2018 $2.37M $2.37M Completed Pre-Clinical Trials
To view ImmunoScape’s complete valuation and funding history, request access »

ImmunoScape Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B2
Series B
Series A 89,843 $26.39 $26.39 1x $26.39 6.9%
To view ImmunoScape’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

ImmunoScape Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immune profiling system and analytical tools designed to support immunotherapy clinical development. The
Discovery Tools (Healthcare)
Singapore, Singapore
23 As of 2026

Marseille, France
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmunoScape Competitors (2)

One of ImmunoScape’s 2 competitors is ImCheck Therapeutics, a Formerly VC-backed company based in Marseille, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImCheck Therapeutics Formerly VC-backed Marseille, France
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 2 of 2 competitors. Get the full list »

ImmunoScape Patents

  • 18

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

ImmunoScape Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026125765-A1 Combination therapy Pending 13-Dec-2024
WO-2026125718-A1 Human t cell receptors and uses thereof Pending 13-Dec-2024
WO-2025181329-A1 Human t cell receptors and uses thereof Pending 01-Mar-2024
WO-2025146286-A1 Human t cell receptors and uses thereof Inactive 04-Jan-2024
US-20250262242-A1 Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof Pending 15-Jun-2022 A61K35/17
To view ImmunoScape’s complete patent history, request access »

ImmunoScape Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunoScape Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
NPR Holdings Venture Capital Minority
ScaleReady Corporation
Amgen Ventures Corporate Venture Capital Minority
EDBI Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

ImmunoScape FAQs

  • When was ImmunoScape founded?

    ImmunoScape was founded in 2016.

  • Where is ImmunoScape headquartered?

    ImmunoScape is headquartered in Singapore, Singapore.

  • What is the size of ImmunoScape?

    ImmunoScape has 23 total employees.

  • What industry is ImmunoScape in?

    ImmunoScape’s primary industry is Discovery Tools (Healthcare).

  • Is ImmunoScape a private or public company?

    ImmunoScape is a Private company.

  • What is ImmunoScape’s current revenue?

    The current revenue for ImmunoScape is .

  • How much funding has ImmunoScape raised over time?

    ImmunoScape has raised $60.4M.

  • Who are ImmunoScape’s investors?

    , NPR Holdings, ScaleReady, Amgen Ventures, and EDBI are 5 of 9 investors who have invested in ImmunoScape.

  • Who are ImmunoScape’s competitors?

    ImCheck Therapeutics and Kite Pharma are competitors of ImmunoScape.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process